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INTRODUCTION
he expression of CD44 molecule has been correlated to
carcinogenesis and aggressive biological behavior of sev-
eral malignant tumors. CD44 is a polymorphic family of cell sur-
face proteoglycans and glycoproteins implicated in cell-cell and
cell-matrix adhesion interactions, lymphocyte activation and hom-
ing, cell migration and tumor metastasis (1-3). CD44 protein is
encoded by a gene located on 11p13 chromosome and consists
of at least 20 exons. Polypeptide isoforms of CD44 are produced
by alternative splicing of at least 10 of the 20 exons during mRNA
processing (3). The simplest CD44 isoform (CD44 standard or
CD44s) does not contain any additional exon product and is
expressed by hematopoietic cells and most epithelial cells.
Various combinations of variant isoforms (CD44v), containing the
product of one or more additional exons, are expressed by normal
epithelial cells and by leucocytes (4). 
Interest has recently focused on the abnormal transcription of
CD44 variants by cancer cells, and on their role in local invasion
and metastatic dissemination (4). Alternations in the composition
of CD44 protein and of its isoforms are associated with neoplas-
tic transformation and metastasis in a number of different tissues.
So, increased expression of CD44 has been implicated in
melanoma metastasis (5), pancreatic adenocarcinomas, colorec-
tal carcinomas (6), non-Hodgkin lymphomas and breast and lung
carcinomas (7). On the other side, decreased expression of
CD44v6 is related to tumor recurrence and unfavorable outcome
in poorly differentiated squamous cell (7) and laryngeal carcino-
mas, as well as in superficial bladder (8) and prostate carcinomas
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Immunohistochemical expression of CD44
in thyroid gland lesions
T
BACKGROUND: CD44 is a polymorphic family of cell surface proteoglycans and glyco-
proteins implicated in cell-to-cell and cell-to-matrix adhesion interactions and tumor
metastasis. Its expression appears to be an indicator of invasive and metastatic behav-
ior in carcinomas. The purpose of our study is to investigate the immunohistochemical
expression of CD44 protein in thyroid lesions and its association to other histopatho-
logical parameters. 
METHODS: Samples from thyroid lesions were obtained from 40 patients treated in our
hospital. The material consisted of 5 cases of multinodular goiter, 7 cases of thyroidi-
tis (Hashimoto type), 5 cases of follicular adenoma, 4 cases of Hurthle cell tumor, 15
cases of thyroid carcinoma (11 papillary carcinomas, and 4 myeloid tumors), and 4
cases of normal thyroid tissue. Immunostaining was performed using the Ventana ES
automated immunostainer. A monoclonal antibody was used and avidin-biotin method
was applied to paraffin-embedded samples. A membranous immunostaining pattern
was considered positive.
RESULTS: CD44 expression was detected in three adenomas (60%), mostly of follicu-
lar type, and in eight carcinomas (72%). The CD44 immunostaining was especially
apparent in papillary type of carcinomas, which showed high expression. In normal thy-
roid tissue, a reduced CD44 expression was observed.
CONCLUSION: The results of our study indicate that deregulated expression of CD44
contributes to the ability of thyroid carcinomas for invasion and metastasis and may
constitute a prognostic factor for malignant biological behavior.
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5(9,10). CD44 variant isoforms are also expressed in normal and
neoplastic thyroid tissue, but it is unclear whether they have any
prognostic value in differentiated thyroid carcinoma (DTC) (9).
DTC, which includes papillary and follicular carcinomas and their
subtypes, is a rather common endocrine malignancy. Although
the majority of patients have usually a mild clinical course and
favorable prognosis, they often present with metastasis to region-
al lymph nodes and occasionally with invasion of local neck
structures. Blood vessel invasion or distant metastases are
uncommon. Despite these interesting biological properties, very
little is known about the molecular factors involved in the patho-
genesis and metastatic properties of this neoplasm (3). 
In the present report, we investigated the immunohistochemical
expression of CD44 protein in benign and malignant thyroid
lesions, we evaluated the possible alternations in its expression
and we associated our results with other classical clinicopatho-
logic parameters.
PATIENTS AND METHODS
Samples from thyroid lesions were obtained in 40 patients (34
women and 6 men) aged 45 through 50 years, treated in our hos-
pital. The material comprised: 5 cases of multinodular goiter, 7
cases of thyroiditis (Hashimoto type), 5 cases of follicular ade-
noma, 4 Hurthle cell neoplasms and 15 cases of thyroid carcino-
ma (11 papillary and 4 medullary carcinomas) (Table 1).
At the same time, samples from 4 normal thyroid glands, excised
for another reason, were examined. Avidin-biotin-peroxidase
(ABC) method was applied to paraffin-embedded samples, using
the Ventana ES automated immunostainer. The monoclonal anti-
body antihuman phagocytic glycoprotein-1, CD44 (DAKO), 1:50
was used. 
The stained slides were examined microscopically. Counting of
CD44 positive cells was performed on the most characteristic
areas. The percentage of positive cells was evaluated by counting
10 high magnification power fields (x40) in three consecutive tis-
sue sections, using semiquantitative criteria: 0= negative; 1+=
less than 25% positive staining; 2+= 25%-50% positive staining;
3+= greater than 50% positive area. The cellular intensity of the
stain was recorded as weak, moderate or strong. A continuous
membranous immunoreactivity was considered positive. Neither
cytoplasmic staining alone nor punctate membrane staining was
considered positive (Figures 1-4).
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Figure 1. CD44 expression in multinodular goiter (x100)
Table 1. Histopathological diagnoses in 40 cases examined
Figure 2. CD44 expression in a case of thyroiditis (Hashimoto type) (x100)
Figure 3. Follicular adenoma, CD44 expression (x100)RESULTS 
The results of our study are summarized in Table 2. 
Intense immunoreactivity with anti-CD44 was observed in 4 of the
11 thyroid papillary carcinomas (36%) and moderate immunos-
taining was also observed in 4 cases (36%), while in the rest 3
cases (27%) there was weak or no membranous staining. None
of the 4 medullary carcinomas (100%) expressed CD44. The 5
adenomas presented a variety of immunoreactivity; two of them
(40%) expressed intense immunostaining, one adenoma (20%)
presented moderate staining and the rest of them (40%) present-
ed weak immunoreactivity. In the 5 cases of multinodular goiter a
wide range of CD44 expression was present; in two of them
(40%) a weak immunostaining was observed, while the rest three
cases presented intense (20%), moderate (20%) and no staining
(20%) correspondingly. Six of seven cases of thyroiditis (85%)
presented weak or no staining at all and only in one case (14%)
an intense positivity with anti-CD44 was observed. A similar
expression of CD44 was present in the 4 Hurthle cell tumors;
three of them (75%) were not immunoreactive for anti-CD44 and
only one case (25%) presented an intense staining. In the 4 cases
of normal thyroid tissue (100%) a weak or negative CD44 expres-
sion was observed.
DISCUSSION
The present study concerns material of archives, which was
immunohistochemically examined. Immunohistochemistry is an
easily applicable and relatively fast and cheap procedure (10). We
analyzed CD44 expression in benign and malignant thyroid
lesions and we correlated it to other histopathological parameters.
Four from 11 papillary thyroid carcinomas presented an intense
immunostaining and in 4 cases we observed a moderate staining.
This fact is according to mild biological behavior and excellent
prognosis of these neoplasms. The 5 cases of adenoma
expressed a variety of staining, with a propensity to moderate and
intense immunoreactivity. In the 5 cases of multinodular goiter we
also observed a width of CD44 expression, a finding that is prob-
ably related to the functional condition of follicular cells. Six of
seven cases of thyroiditis (Hashimoto type) presented weak or
negative CD44 expression and only in one case we observed
intense immunostaining. Similar expression was present in the 4
Hurthle cell tumors, three of which showed negative expression
and only one showed intense immunoreactivity. This fact is prob-
ably related to metaplastic epithelial alterations observed in these
lesions. In the samples of normal thyroid tissue we observed a
reduced expression of CD44.
CD44 and its isoforms have been described in normal epithelia
such as the basal layer of esophagus, the myoepithelial cells of
the breast, the pneumocytes and bronchial epithelium, the base of
the crypts of the small and large intestine, but also in various
human cancers, including mammary, esophageal, gastric, lung
and colon cancers. In human epithelial tumors, CD44 variants,
although preferentially localized to the neoplastic cells, are also
weakly expressed by the adjacent normal tissues (6). The pres-
ence of CD44 isoforms on cancerous cells has been correlated to
tumor stage and prognosis. Elevated expression of CD44 is asso-
ciated with the metastatic potential of malignant melanoma
(Regauer et al.) (5). Durai et al. and Saegusa et al.   show that
malignant as well as borderline tumors of the ovary usually
express a large spectrum of CD44 isoforms, in contrast to benign
tumors (4,12). Several authors (6) have noted the correlation
between CD44v6 expression and high metastatic potential with
poor outcome in mammary, nasopharyngeal, non-small cell lung
carcinoma and non-Hodgkin’s lymphoma. Later on, it became
evident that CD44v6 may be a good marker of tumor progression
and metastasis in some types of tumors, but it can have no cor-
relation or inverse correlation in other settings, like squamous-cell
carcinomas (Hudson et al.) (7). In colorectal tumors, the signifi-
cance of CD44v6 expression remains to be defined. The associ-
ation of CD44 expression with higher stage of disease and
metastatic potential is contradictory. Coppola et al. (6), using
immunohistochemistry and Western-blot analysis, described the
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Figure 4. Papillary thyroid carcinoma, CD44 expression (x100)
Table 2. Relation between CD44 expression and histopathological diagnoses in
the examined casespredominant CD44v6 expression in colorectal adenocarcinomas
and its loss at the metastatic site. Because little is known about
the functions of the CD44 isoforms, additional experiments are
required to exactly define relevant isoforms and their biological
role (3). In differentiated thyroid carcinoma it is unclear whether
the deregulated expression of CD44 has any prognostic value (9). 
Most of our bibliographic reports are based on PCR studies.
Ermak et al. applying PCR and hybridization technique, describe
that papillary thyroid carcinomas, adenomas and multinodular
goiters exhibit a generalized increase in CD44mRNA isoforms,
distinguishing them from histologically normal thyroid tissue
(3,13). Studies have also been made about CD44 immunostain-
ing in thyroid fine-needle aspirates of papillary carcinoma. Ross
et al. conclude that the majority of thyroid papillary carcinomas
express CD44 immunoreactivity in a membranous pattern, in con-
trast to normal follicular cells and nonpapillary carcinoma thyroid
lesions, even those with cytologic features suggestive of papillary
carcinoma (11,14).
Abnormalities in CD44 isoform expression are associated gener-
ally with a disordered growth state of the follicular cells. The
deregulated expression of CD4 may be involved directly in the
pathogenesis of these disordered growth states, given the known
role of CD44 in cell-cell and cell-matrix adhesion. Alterations in
CD44 isoform expression on the cell surface could change cell-
cell interactions or interactions with macromolecules, such as
collagen, fibronectin, and hyaluronate, in the extracellular matrix,
resulting in a disordered growth pattern. Therefore, it is possible
that deregulation of CD44mRNA processing is a very early step in
the pathway of successive molecular events that lead to develop-
ment of papillary cancer (13). The selective expression of CD44
cell-adhesion molecule in thyroid papillary carcinoma, in addition
to the potential diagnostic value, may have relevance in predicting
disease progression. The expression of this lymphocyte homing
and attachment molecule may explain the propensity for this
tumor to involve regional lymph nodes (11).
CONCLUSION
In conclusion, the results of our study indicate that most papillary
carcinomas of the thyroid express the cell-adhesion molecule
CD44, in contrast to other neoplastic and nonneoplastic thyroid
lesions and normal follicular cells. It seems that deregulated
expression of CD44 plays a role in the carcinogenesis of thyroid
gland and possibly contributes to the mild biological behaviour of
differentiated papillary carcinomas. However, a greater number of
cases and further studies of CD44 activity are needed in order to
evaluate CD44 expression in thyroid gland lesions and determine
this molecule as a prognostic marker.
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